Colesevelam Administration Guidelines

Administration Requirements

The American College of Cardiology recommends taking colesevelam tablets with a meal and liquid, 6 tablets once daily or 3 tablets twice daily 1, 2, 3, 4, 5
The American College of Cardiology suggests mixing one 3.75-gram packet of colesevelam oral suspension once daily or one 1.875-gram packet twice daily with 4-8 ounces of water, fruit juice, or diet soft drink, and taking with a meal 1, 2, 3, 4, 5

Colesevelam binds bile acids in the intestine, which are released during digestion of meals, according to the American College of Cardiology 2, 3, 4, 5
Taking colesevelam with food ensures optimal interaction with bile acids released during the digestive process, as recommended by the American College of Cardiology 2, 4
This timing maximizes the drug's ability to sequester bile acids and achieve its lipid-lowering effect, according to the American College of Cardiology 2, 5

The American College of Cardiology advises taking other medications at least 1 hour before or 4 hours after colesevelam to avoid impaired absorption 1, 2, 3, 4, 5, 6
This is particularly critical for medications with narrow therapeutic windows, including thyroid hormone replacement, warfarin, phenytoin, and oral contraceptives, as noted by the American College of Cardiology and Clinical Gastroenterology and Hepatology 1, 2, 3, 4, 5, 6

The American College of Cardiology recommends scheduling colesevelam with breakfast and/or dinner 1, 2, 3, 4, 5
Clinical Gastroenterology and Hepatology suggests taking other medications either first thing in the morning (1+ hours before colesevelam) or at bedtime (4+ hours after colesevelam) 6, 5

The American College of Cardiology reports that constipation, dyspepsia, and nausea are the most common gastrointestinal side effects of colesevelam 1, 2, 3, 4, 5
Taking colesevelam with adequate liquid may help mitigate some GI symptoms, according to the American College of Cardiology 1, 2, 3, 4, 5

The American College of Cardiology recommends a dose of 3.75 grams daily, administered either as 6 tablets (625 mg each) once daily or 3 tablets twice daily with meals, for adults with primary hyperlipidemia 7
The American College of Cardiology also recommends one 3.75-gram oral suspension packet once daily mixed with 4-8 ounces of liquid and taken with a meal for adults with primary hyperlipidemia 7

Colesevelam 3.75 grams daily as monotherapy reduces LDL-C by approximately 15% 7
When added to low- to moderate-intensity statins, colesevelam provides an additional 10-16% reduction in LDL-C 7

The American College of Cardiology recommends colesevelam 3.75 grams daily as adjunct therapy to improve glycemic control in adults with type 2 diabetes, which lowers HbA1c by approximately 0.5% 7
For bile acid diarrhea, colesevelam is typically dosed as 2 tablets (625 mg) three times daily with meals, with a success rate as second-line therapy ranging from 42-100% in observational studies 8

The most common adverse effects of colesevelam are gastrointestinal, including constipation, dyspepsia, and nausea, occurring at rates similar to placebo (approximately 40%) 7, 8
Colesevelam has significantly better tolerability than traditional bile acid sequestrants like cholestyramine 8

Patients requiring oral vitamin supplementation should take vitamins at least 4 hours before colesevelam to avoid impaired absorption 7
The American College of Cardiology recommends monitoring triglyceride levels before starting and periodically during therapy with colesevelam, as it may increase triglycerides 7

The standard dose for bile‑acid sequestration is 3.75 g per day, administered either as six 625 mg tablets once daily with a meal or three 625 mg tablets twice daily with meals【9】.
An oral suspension formulation is available: one 3.75‑g packet taken once daily with a meal (mixed with water, juice, or diet soft drink) or two 1.875‑g packets taken twice daily with meals【9】.

As monotherapy, colesevelam 3.75 g daily lowers LDL‑C by approximately 15–20 %; some studies report reductions up to 18–25 % at the maximum dose【9】【10】.
When added to low‑ or moderate‑intensity statin therapy, colesevelam provides an additional 10–16 % LDL‑C reduction beyond the statin effect【9】.
In patients with severe hypercholesterolemia already on maximal statin + ezetimibe therapy, colesevelam 3.75 g daily yields an extra 18.5 % LDL‑C reduction over 12 weeks【11】.

Colesevelam must be taken with food to ensure binding of bile acids released during digestion【9】.
All other oral medications should be administered ≥ 4 hours before or ≥ 1 hour after colesevelam; this is critical for drugs with narrow therapeutic windows such as thyroid hormone replacement, phenytoin, and cyclosporine【9】.

Unlike older bile‑acid sequestrants, colesevelam does not require dose titration; the 3.75 g/day regimen can be started immediately【12】【13】.
For off‑label use in bile‑acid diarrhea, the typical regimen is two 625 mg tablets three times daily with meals (total 3.75 g/day); a gradual titration may be employed to lessen gastrointestinal side effects【12】【13】.

Pediatric patients (ages 10–17) with heterozygous familial hypercholesterolemia may receive the adult regimen of 3.75 g daily (six tablets once daily or three tablets twice daily with meals) when LDL‑C remains markedly elevated after diet and risk‑factor assessment【14】【9】.
In type 2 diabetes, colesevelam 3.75 g daily produces a ≈ 0.5 % reduction in HbA1c, offering a dual benefit of lipid‑lowering and modest glycemic improvement【10】.

The most common adverse events are gastro‑intestinal (constipation, dyspepsia, nausea), occurring at rates similar to placebo (~40 %)【9】【12】.
Colesevelam demonstrates significantly better tolerability than traditional bile‑acid sequestrants such as cholestyramine【12】【13】.
Baseline lipid panel (including triglycerides) should be obtained before initiating therapy, and triglyceride levels should be monitored periodically because colesevelam can increase triglycerides【9】【10】.

Class‑effect data from the LRC‑CPPT trial of cholestyramine showed a reduction in coronary heart disease events proportional to LDL‑C lowering, supporting the expected cardiovascular benefit of bile‑acid sequestration【10】.
Although colesevelam lacks dedicated outcome trials, its LDL‑C‑lowering magnitude aligns with Mendelian randomization analyses predicting cardiovascular risk reduction【11】.